AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound having the generalized structural formula



I.

wherein

R^1 and R^2

together form a bridge containing two T^2 moieties and one T^3 moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure



wherein

each T^2 independently represents [[N,]]CH, or CG^1; and

T^3 represents ~~S, O, CR^4G^1, $C(R^4)_2$, or NR^3~~ $\underline{CR^4G^1 \text{ or } C(R^4)_2}$;

and wherein

G^1 is a substituent independently selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;

- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-OCOR^6$;
- $-COR^6$;

- $-CO_2R^6$;
- $-CON(R^6)_2$;
- $-CH_2OR^3$;
- $-NO_2$;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)2 ;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted saturated heterocyclylalkyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclylalkyl;
- $-OCO_2R^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$(optionally substituted heteroarylalkyl);
- -CHO;
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$

R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- alkyl;
- cycloalkyl;
- optionally substituted aryl; and
- optionally substituted aryl lower alkyl;
- lower alkyl-$N(R^3)_2$; and
- lower alkyl-OH;

R^4 is H, halogen, or lower alkyl;

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NR^3;

Y is selected from the group consisting of

- lower alkylene;
- $-CH_2-O-$;
- $-CH_2-S-$;
- $-CH_2-NH-$;
- -O- ;
- -S- ;
- -NH- ;
- $-(CR^4_2)_n-S(O)_p-$(5-membered heteroaryl)$-(CR^4_2)_s-$;
- $-(CR^4_2)_n-C(G^2)(R^4)-(CR^4_2)_s-$;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G^2 is selected from the group consisting of -CN, $-CO_2R^3$, $-CON(R^6)_2$, and – $CH_2N(R^6)_2$;

- $-O-CH_2-$;
- -S(O)- ;
- $-S(O)_2-$;

- $-SCH_2-$;
- $-S(O)CH_2-$;
- $-S(O)_2CH_2-$;
- $-CH_2S(O)-$; and
- $-CH_2S(O)_2-$

Z is ~~CR^4 or~~ N;

q is 0, 1, or 2;

G^3 is a monovalent or bivalent moiety selected from the group consisting of:

- lower alkyl;
- $-NR^3COR^6$;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CH_2OR^3$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- $-NO_2$;
- -CN;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;

- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$(optionally substituted heteroarylalkyl);
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$; and
- bivalent bridge of structure $T^2=T^2-T^3$

  wherein

  each T^2 independently represents N, CH, or $CG^{3'}$; and

  T^3 represents S, O, $CR^4G^{3'}$, $C(R^4)_2$, or NR^3; wherein

  $G^{3'}$ represents any of the above-defined moieties G^3 which are monovalent; and

  the terminal T^2 is bound to L, and T^3 is bound to D, forming a 5-membered fused ring;

A and D independently represent N or CH;

B and E independently represent N or CH;

L represents N or CH; and

with the provisos that

a) the total number of N atoms in the ring containing A, B, D, E, and L is 0, 1, 2, or 3; and

b) when L represents CH and q=0 or any G^3 is a monovalent substituent, at least one of A and D is an N atom; and

c) when L represents CH and a G^3 is a bivalent bridge of structure $T^2=T^2-T^3$, then A, B, D, and E are also CH;

J is a ring selected from the group consisting of

- aryl;
- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and

G^4 is a monovalent or bivalent moiety selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;

- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CON(R^6)_2$;
- $-CH_2OR^3$;
- $-NO_2$;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)2 ;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- $-OCO_2R^3$;
- optionally substituted heteroarylalkyl;

- optionally substituted heteroaryloxy;
- $-S(O)_p$(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$(optionally substituted heteroarylalkyl);
- -CHO;
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$; and
- fused ring-forming bivalent bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)

wherein

each T^2 independently represents N, CH, or $CG^{4'}$;

T^3 represents S, O, $CR^4G^{4'}$, $C(R^4)_2$, or NR^3; wherein

G4' represents any of the above-defined moieties G^4 which are monovalent; and

binding to ring J is achieved via terminal atoms T^2 and T^3;

b)

wherein

each T^2 independently represents N, CH, or $CG^{4'}$; wherein

G4' represents any of the above-defined moieties G^4 which are monovalent; and

with the proviso that a maximum of two bridge atoms T^2 may be N ; and

binding to ring J is achieved via terminal atoms T^2; and

c)



wherein

each T^4, T^5, and T^6 independently represents O, S, $CR^4G^{4'}$, $C(R^4)_2$, or NR^3;

wherein

G4' represents any of the above-defined moieties G^4 which are monovalent; and

binding to ring J is achieved via terminal atoms T^4 or T^5;

with the provisos that:

i) when one T^4 is O, S, or NR^3, the other T^4 is $CR^4G^{4'}$ or $C(R^4)_2$;

ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and

iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

when G^4 is an alkyl group located on ring J adjacent to the linkage $-(CR^4_2)_{p'}-$, and X is NR^3 wherein R^3 is an alkyl substituent, then G^4 and the alkyl substituent R^3 on X may be joined to form a bridge of structure $-(CH_2)_{p'}-$ wherein p' is 2, 3, or 4, with the proviso that the sum of p and p' is 2, 3, or 4, resulting in formation of a nitrogen-containing ring of 5, 6, or 7 members;

and with the further provisos that:

- in G^1, G^2, G^3, and G^4, when two groups R^3 or R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms;

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower

alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, -CHO, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCON(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano; and

- when any alkyl group is attached to O, S, or N, and bears a hydroxyl substituent, then said hydroxyl substituent is separated by at least two carbon atoms from the O, S, or N to which the alkyl group is attached,

or a pharmaceutically acceptable salt or prodrug thereof.

2. (Currently Amended) A compound of claim 1 wherein

R^1 and R^2

together form a bridge containing two T^2 moieties and one T^3 moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure



wherein

each T^2 independently represents [[N,]]CH, or CG^1; and

T^3 represents ~~S, O,~~ CH_2, ~~or NR^3~~;

~~with the proviso that when T^3 is O or S, at least one T^2 is CH or CG^1~~.

3. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4. (Withdrawn) A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes, comprising administering to said mammal an amount of a compound of claim 1 which is effective to treat said condition.

5. (Withdrawn) The method of claim 4, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.

6. (Currently Amended) A compound having the generalized structural formula

II. 

wherein

R^1 and R^2 :

i) independently represent H or lower alkyl;

ii) together form a bridge of structure

wherein binding is achieved via the terminal carbon atoms;

iii) together form a bridge of structure

wherein binding is achieved via the terminal carbon atoms;

~~iv) together form a bridge of structure~~



~~wherein one or two ring members T^1 are N and the others are CH or CG^1, and binding is achieved via the terminal atoms;~~ or

v) together form a bridge containing two T^2 moieties and one T^3 moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure



wherein

each T^2 independently represents [[N,]]CH, or CG^1; and

T^3 represents ~~S, O,~~ CR^4G^1, or $C(R^4)_2$, ~~or NR^3~~;

and wherein

m is 0 or an integer 1 – 4; and

G^1 is a substituent independently selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;

- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CON(R^6)_2$;
- $-CH_2OR^3$;
- $-NO_2$;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)2 ;

- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted saturated heterocyclylalkyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclylalkyl;
- $-OCO_2R^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$(optionally substituted heteroarylalkyl);
- -CHO;
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$

R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- alkyl;
- cycloalkyl;
- optionally substituted aryl; and
- optionally substituted aryl lower alkyl;
- lower alkyl-$N(R^3)_2$; and
- lower alkyl-OH;

R^4 is H, halogen, or lower alkyl;

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NR^3;

Y is selected from the group consisting of

- lower alkylene;
- $-CH_2-O-$;
- $-CH_2-S-$;
- $-CH_2-NH-$;
- -O- ;
- -S- ;
- -NH- ;
- $-(CR^4{}_2)_n-S(O)_p-$(5-membered heteroaryl)$-(CR^4{}_2)_s-$;
- $-(CR^4{}_2)_n-C(G^2)(R^4)-(CR^4{}_2)_s-$;

  wherein

  n and s are each independently 0 or an integer of 1 – 2; and

  G^2 is selected from the group consisting of -CN, $-CO_2R^3$, $-CON(R^6)_2$, and – $CH_2N(R^6)_2$;
- $-O-CH_2-$;
- -S(O)- ;
- $-S(O)_2-$;
- $-SCH_2-$;
- $-S(O)CH_2-$;
- $-S(O)_2CH_2-$;
- $-CH_2S(O)-$; and
- $-CH_2S(O)_2-$

Z is N ~~or CR^4~~;

q is 1 or 2;

G^3 is a monovalent or bivalent moiety selected from the group consisting of

- lower alkyl;
- $-NR^3COR^6$;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CH_2OR^3$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- $-NO_2$;
- -CN;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$(optionally substituted heteroarylalkyl);
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;

- $-NR^3CON(R^6)_2$; and
    - bivalent bridge of structure $T^2=T^2-T^3$:

        wherein

        each T^2 independently represents N, CH, or $CG^{3'}$; and

        T^3 represents S, O, $CR^4G^{3'}$, $C(R^4)_2$, or NR^3 ; wherein

        $G^{3'}$ represents any of the above-defined moieties G3 which are monovalent; and

        the terminal T^2 is bound to L, and T^3 is bound to D, forming a 5-membered fused ring;

    A and D are CH;

    B and E are CH;

    L is CH;

    with the proviso that the resulting phenyl ring bears as a G^3 substituent said bivalent bridge of structure $T^2=T^2-T^3$;

J is a ring selected from the group consisting of

- aryl;
- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and

G^4 is a monovalent or bivalent moiety selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;

- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;

- -CON(R^6)$_2$;
- -CH_2OR^3;
- -NO_2 ;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)2 ;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- -OCO_2R^3;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)$_p$(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)$_p$(optionally substituted heteroarylalkyl);
- -CHO;
- -OCON(R^6)$_2$;
- -$NR^3CO_2R^6$;
- -NR^3CON(R^6)$_2$; and
    - fused ring-forming bivalent bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)

wherein

each T^2 independently represents N, CH, or $CG^{4'}$;

T^3 represents S, O, $CR^4G^{4'}$, $C(R^4)_2$, or NR^3; wherein

$G^{4'}$ represents any of the above-defined moieties G^4 which are monovalent; and

binding to ring J is achieved via terminal atoms T^2 and T^3;

b)

wherein

each T^2 independently represents N, CH, or $CG^{4'}$; wherein

G4' represents any of the above-defined moieties G^4 which are monovalent; and

with the proviso that a maximum of two bridge atoms T^2 may be N ; and

binding to ring J is achieved via terminal atoms T^2; and

c)



wherein

each T^4, T^5, and T^6 independently represents O, S, $CR^4G^{4'}$, $C(R^4)_2$, or NR^3;

wherein

G4' represents any of the above-identified moieties G4 which are monovalent; and

binding to ring J is achieved via terminal atoms T^4 or T^5 ;

with the provisos that:

i) when one T^4 is O, S, or NR^3, the other T^4 is $CR^4G^{4'}$ or $C(R^4)_2$;

ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and

iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

when G^4 is an alkyl group located on ring J adjacent to the linkage $-(CR^4_2)_{p'}-$, and X is NR^3 wherein R^3 is an alkyl substituent, then G^4 and the alkyl substituent R^3 on X may be joined to form a bridge of structure $-(CH_2)_{p'}-$ wherein p' is 2, 3, or 4, with the proviso that the sum of p and p' is 2, 3, or 4, resulting in formation of a nitrogen-containing ring of 5, 6, or 7 members;

and with the further provisos that:

- in G^1, G^2, G^3, and G^4, when two groups R^3 or R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms;

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, -CHO, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCON(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano; and

- when any alkyl group is attached to O, S, or N, and bears a hydroxyl substituent, then said hydroxyl substituent is separated by at least two carbon atoms from the O, S, or N to which the alkyl group is attached,

or a pharmaceutically acceptable salt or prodrug thereof.

7. (Original) A compound of claim 6 wherein, in the ring comprising A, B, D, E, and L and a bivalent bridge of structure $T^2=T^2-T^3$, the terminal T^2 represents N and the T^3 unit of said bridge represents S, O, CR^4_2, or NR^3.

8. (Original) A pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier.

9. (Withdrawn) A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes, comprising administering to said mammal an amount of a compound of claim 6 which is effective to treat said condition.

10. (Withdrawn) The method of claim 9, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.

11. (Withdrawn) A compound having the generalized structural formula

III. 

wherein

R^1 and R^2 :

i) independently represent H or lower alkyl;

ii) together form a bridge of structure

wherein binding is achieved via the terminal carbon atoms;

iii) together form a bridge of structure

wherein binding is achieved via the terminal carbon atoms;

iv) together form a bridge of structure

wherein one or two ring members T^1 are N and the others are CH or CG^1, and binding is achieved via the terminal atoms; or

v) together form a bridge containing two T^2 moieties and one T^3 moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure



wherein

each T^2 independently represents N, CH, or CG^1; and

T^3 represents S, O, CR^4G^1, $C(R^4)_2$, or NR^3;

and wherein

m is 0 or an integer 1 – 4; and

G^1 is a substituent independently selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;

- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CON(R^6)_2$;
- $-CH_2OR^3$;
- $-NO_2$;

- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)2 ;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted saturated heterocyclylalkyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclylalkyl;
- $-OCO_2R^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$(optionally substituted heteroarylalkyl);
- -CHO;
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$

R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- alkyl;
- cycloalkyl;
- optionally substituted aryl; and

- optionally substituted aryl lower alkyl;
- lower alkyl-$N(R^3)_2$; and
- lower alkyl-OH;

R^4 is H, halogen, or lower alkyl;

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NR^3;

Y is selected from the group consisting of

- lower alkylene;
- $-CH_2-O-$;
- $-CH_2-S-$;
- $-CH_2-NH-$;
- -O- ;
- -S- ;
- -NH- ;
- $-(CR^4_2)_n-S(O)_p-$(5-membered heteroaryl)$-(CR^4_2)_s-$;
- $-(CR^4_2)_n-C(G^2)(R^4)-(CR^4_2)_s-$;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G^2 is selected from the group consisting of -CN, $-CO_2R^3$, $-CON(R^6)_2$, and – $CH_2N(R^6)_2$;

- $-O-CH_2-$;
- -S(O)- ;
- $-S(O)_2-$;
- $-SCH_2-$;
- $-S(O)CH_2-$;
- $-S(O)_2CH_2-$;

- $-CH_2S(O)-$; and
- $-CH_2S(O)_2-$

Z is CR^4;

q is 1 or 2;

G^3 is a monovalent or bivalent moiety selected from the group consisting of

- $-NR^3COR^6$;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CH_2OR^3$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- $-NO_2$;
- -CN;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$(optionally substituted heteroaryl);

- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$(optionally substituted heteroarylalkyl);
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$; and
  - bivalent bridge of structure $T^2=T^2-T^3$

    wherein

    each T^2 independently represents N, CH, or $CG^{3'}$; and

    T^3 represents S, O, $CR^4G^{3'}$, $C(R^4)_2$, or NR^3; wherein

    $G^{3'}$ represents any of the above-defined moieties G^3 which are monovalent; and

    the terminal T^2 is bound to L, and T^3 is bound to D, forming a 5-membered fused ring;

A and D independently represent N or CH;

B and E independently represent N or CH;

L represents N or CH;

with the provisos that

a) the total number of N atoms in the ring containing A, B, D, E, and L is 0, 1, 2, or 3; and

b) when L represents CH and any G^3 is a monovalent substituent, at least one of A and D is an N atom; and

c) when L represents CH and a G^3 is a bivalent bridge of structure $T^2=T^2-T^3$, then A, B, D, and E are also CH;

J is a ring selected from the group consisting of

- aryl;
- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and

G^4 is a monovalent or bivalent moiety selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;

- -OR^6;
- -SR^6;
- -$S(O)R^6$;
- -$S(O)_2R^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -$OCOR^6$;
- -COR^6;
- -CO_2R^6;
- -$CON(R^6)_2$;
- -CH_2OR^3;
- -NO_2 ;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)2 ;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- -OCO_2R^3;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -$S(O)_p$(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -$S(O)_p$(optionally substituted heteroarylalkyl);
- -CHO;

- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$; and
  - fused ring-forming bivalent bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)

wherein

each T^2 independently represents N, CH, or $CG^{4'}$;

T^3 represents S, O, $CR^4G^{4'}$, $C(R^4)_2$, or NR^3; wherein

G4' represents any of the above-defined moieties G4 which are monovalent; and

binding to ring J is achieved via terminal atoms T^2 and T^3;

b)

wherein

each T^2 independently represents N, CH, or $CG^{4'}$; wherein

G4' represents any of the above-defined moieties G4 which are monovalent; and

with the proviso that a maximum of two bridge atoms T^2 may be N ; and

binding to ring J is achieved via terminal atoms T^2; and

c)

wherein

each T^4, T^5, and T^6 independently represents O, S, $CR^4G^{4'}$, $C(R^4)_2$, or NR^3;

wherein

G4' represents any of the above-defined moieties G4 which are monovalent; and

binding to ring J is achieved via terminal atoms T^4 or T^5 ;

with the provisos that:

i) when one T^4 is O, S, or NR^3, the other T^4 is $CR^4G^{4'}$ or $C(R^4)_2$;

ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and

iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

when G^4 is an alkyl group located on ring J adjacent to the linkage $-(CR^4_2)_p-$, and X is NR^3 wherein R^3 is an alkyl substituent, then G^4 and the alkyl substituent R^3 on X may be joined to form a bridge of structure $-(CH_2)_{p'}-$ wherein p' is 2, 3, or 4, with the proviso that the sum of p and p' is 2, 3, or 4, resulting in formation of a nitrogen-containing ring of 5, 6, or 7 members;

and with the further provisos that:

- in G^1, G^2, G^3, and G^4, when two groups R^3 or R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms;

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, -CHO, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCON(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano; and

- when any alkyl group is attached to O, S, or N, and bears a hydroxyl substituent, then said hydroxyl substituent is separated by at least two carbon atoms from the O, S, or N to which the alkyl group is attached,

or a pharmaceutically acceptable salt or prodrug thereof.

12. (Withdrawn)A compound of claim 11 wherein R^4 is H.

13. (Withdrawn)A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier.

14. (Withdrawn)A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes, comprising administering to said mammal an amount of a compound of claim 11 which is effective to treat said condition.

15. (Withdrawn)The method of claim 14, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.

16. (Currently Amended) A compound selected from the group consisting of

Ex. No.:	Compound Name (IUPAC):
1	N-(4-chlorophenyl)-4-(4-pyridinylsulfanyl)-1-isoquinolinamine
2	N-(2,3-dihydro-1H-inden-5-yl)-4-(4-pyridinylsulfanyl)-1-isoquinolinamine
3	N-(1,3-benzothiazol-6-yl)-4-(4-pyridinylsulfanyl)-1-isoquinolinamine
4	N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-isoquinolinamine
5	N-(1,3-benzothiazol-6-yl)-4-(4-pyridinylmethyl)-1-isoquinolinamine
6	N-(2,3-dihydro-1H-inden-5-yl)-4-(4-pyridinylmethyl)-1-isoquinolinamine
7	N-(3-fluoro-4-methylphenyl)-4-(4-pyridinylmethyl)-1-isoquinolinamine
8	N-(4-chlorophenyl)-7-(4-pyridinylmethoxy)thieno[2,3-d]pyridazin-4-amine

9	N-(4-chlorophenyl)-7-(4-pyridinylmethoxy)furo[2,3-d]pyridazin-4-amine
10	4-[({4-[(4-chlorophenyl)amino]thieno[2,3-d]pyridazin-7-yl}oxy)methyl]-2-pyridinecarboxamide
11	4-[({4-[(4-chlorophenyl)amino]thieno[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
12	4-({1-[(4-chlorophenyl)amino]-4-isoquinolinyl}methyl)-2-pyridinecarboxamide
13	4-({1-[(4-chlorophenyl)amino]-4-isoquinolinyl}methyl)-N-methyl-2-pyridinecarboxamide
14	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
16	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-2-pyridinecarboxamide
17	N-(1,3-benzothiazol-6-yl)-N-{4-[(4-chlorophenyl)amino]thieno[2,3-d]pyridazin-7-yl}amine
18	N-(1,3-benzothiazol-6-yl)-N-[4-(2,3-dihydro-1H-inden-5-ylamino)thieno[2,3-d]pyridazin-7-yl]amine
19	4-(5-bromo-2,3-dihydro-1*H*-indol-1-yl)-7-(4-pyridinylmethoxy)furo[2,3-*d*]pyridazine
20	4-[({4-[(4-methoxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
21	N-(4-methoxyphenyl)-7-(4-pyridinylmethoxy)furo[2,3-d]pyridazin-4-amine
22	4-[({4-[(4-methoxyphenyl)amino]furo[2,3-*d*]pyridazin-7-yl}oxy)methyl]-2-pyridinecarboxamide
23	N^7-(1,3-benzothiazol-6-yl)-N^4-(4-chlorophenyl)thieno[2,3-d]pyridazine-4,7-diamine
24	N-(1,3-benzothiazol-6-yl)-N-[4-(2,3-dihydro-1H-inden-5-ylamino)thieno[2,3-d]pyridazin-7-yl]amine
27	N-(1H-indazol-5-yl)-N-[4-(1H-indazol-5-ylamino)thieno[2,3-d]pyridazin-7-yl]amine
28	N-(1,3-benzothiazol-6-yl)-N-[4-(1,3-benzothiazol-6-ylamino)furo[2,3-d]pyridazin-7-yl]amine
34	4-[({4-[(4-methoxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
35	4-[({4-[(3-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
36	4-[({4-[(3-chloro-4-fluorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
37	4-[({4-[(4-fluorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
38	4-[({4-[(4-bromophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
39	N-methyl-4-[({4-[(4-methylphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-2-pyridinecarboxamide

40	N-methyl-4-[({4-[(3-methylphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-2-pyridinecarboxamide
42	N-methyl-4-{[(4-{[4-(trifluoromethyl)phenyl]amino}furo[2,3-d]pyridazin-7-yl)oxy]methyl}-2-pyridinecarboxamide
43	N-methyl-4-{[(4-{[4-(trifluoromethoxy)phenyl]amino}furo[2,3-d]pyridazin-7-yl)oxy]methyl}-2-pyridinecarboxamide
44	4-[({4-[(3-chloro-4-methoxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
45	4-({[4-({4-[acetyl(methyl)amino]phenyl}amino)furo[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide
46	N-methyl-4-{[(4-{[4-(4-morpholinyl)phenyl]amino}furo[2,3-d]pyridazin-7-yl)oxy]methyl}-2-pyridinecarboxamide
47	4-[({4-[(3,4-difluorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
48	N-(1,3-benzothiazol-6-yl)-N-{4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}amine
49	4-({[4-(2,3-dihydro-1H-inden-5-ylamino)furo[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide
50	4-[({4-[(2-methoxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
51	4-[({4-[(3-methoxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
52	4-({[4-(1,3-benzodioxol-5-ylamino)furo[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide
53	4-[({4-[(3,4-dichlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
54	4-[({4-[(3,5-dimethylphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
55	4-({[4-(1H-indazol-5-ylamino)furo[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide
56	N-(4-methoxyphenyl)-7-(4-pyridinylmethoxy)furo[2,3-d]pyridazin-4-amine
57	4-[({4-[(4-hydroxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
58	4-{[7-(4-pyridinylmethoxy)furo[2,3-d]pyridazin-4-yl]amino}phenol
59	4-{[(4-anilinofuro[2,3-d]pyridazin-7-yl)oxy]methyl}-N-methyl-2-pyridinecarboxamide
60	4-[({4-[(3-methoxy-4-methylphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
61	N-(4-chlorophenyl)-7-{[2-(4-morpholinylcarbonyl)-4-pyridinyl]methoxy}furo[2,3-d]pyridazin-4-amine
62	N-methyl-4-[({4-[(2-methyl-1,3-benzothiazol-5-yl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-2-pyridinecarboxamide
63	4-({[4-(1,3-benzothiazol-6-ylamino)furo[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide trifluoroacetate

64	{4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-2-pyridinyl}methanol
65	4-({[4-(2,3-dihydro-1-benzofuran-5-ylamino)furo[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide
66	4-({[4-(2,3-dihydro-1-benzofuran-5-ylamino)thieno[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide
67	4-[({4-[(4-fluorophenyl)amino]thieno[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
68	N-methyl-4-[({4-[(3-methylphenyl)amino]thieno[2,3-d]pyridazin-7-yl}oxy)methyl]-2-pyridinecarboxamide
69	4-[({4-[(4-methoxyphenyl)amino]thieno[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
70	N-methyl-4-{[({4-[(4-(trifluoromethoxy)phenyl]amino}thieno[2,3-d]pyridazin-7-yl)oxy]methyl}-2-pyridinecarboxamide
71	N-methyl-4-{[({4-[(4-[trifluoromethyl)phenyl]amino}thieno[2,3-d]pyridazin-7-yl)oxy]methyl}-2-pyridinecarboxamide
72	4-[({4-[(4-bromophenyl)amino]thieno[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide
73	4-({[4-(2,3-dihydro-1H-inden-5-ylamino)thieno[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide
74	4-({[4-(1,3-benzodioxol-5-ylamino)thieno[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methyl-2-pyridinecarboxamide
75	N-(1,3-benzothiazol-6-yl)-N-[4-(1,3-benzothiazol-6-ylamino)thieno[2,3-d]pyridazin-7-yl]amine
76	N-(1,3-benzothiazol-6-yl)-N-{4-[(4-bromophenyl)amino]thieno[2,3-d]pyridazin-7-yl}amine
78	N-(1,3-benzothiazol-6-yl)-N-{4-[(2,4-dimethylphenyl)amino]thieno[2,3-d]pyridazin-7-yl}amine
79	N-(1,3-benzothiazol-6-yl)-N-{4-[(3-fluoro-4-methylphenyl)amino]thieno[2,3-d]pyridazin-7-yl}amine
82A	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-[2-(dimethylamino)ethyl]-2-pyridinecarboxamide
82B	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-cyclopropyl-2-pyridinecarboxamide
82C	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-(2-hydroxyethyl)-2-pyridinecarboxamide
82D	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-ethyl-2-pyridinecarboxamide
85	N-(4-chlorophenyl)-4-(4-pyridinylsulfanyl)-1-isoquinolinamine
88	N-(2,3-dihydro-1H-inden-5-yl)-4-(4-pyridinylsulfanyl)-1-isoquinolinamine
89	N-(1,3-benzothiazol-6-yl)-4-(4-pyridinylsulfanyl)-1-isoquinolinamine
93	N-(1,3-benzothiazol-6-yl)-N-[4-(1,3-benzothiazol-6-ylamino)-1-phthalazinyl]amine

95	N-(1H-benzimidazol-6-yl)-N-{4-[(4-chlorophenyl)amino]-1-phthalazinyl}amine
96	N-(1H-1,2,3-benzotriazol-5-yl)-N-{4-[(4-chlorophenyl)amino]-1-phthalazinyl}amine
97	N-(1,3-benzothiazol-6-yl)-4-(5-bromo-2,3-dihydro-1H-indol-1-yl)-1-phthalazinamine
98	N-(1,3-benzothiazol-6-yl)-N-{4-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-1-phthalazinyl}amine
99	N-(1,3-benzothiazol-6-yl)-N-(4-{[4-(1-piperidinyl)phenyl]amino}-1-phthalazinyl)amine
100	N-(1,3-benzothiazol-6-yl)-N-[4-({4-[ethyl(isopropyl)amino]phenyl}amino)-1-phthalazinyl]amine
101	N-(1,3-benzothiazol-6-yl)-N-{4-[(3-bromophenyl)amino]-1-phthalazinyl}amine
102	N-(1,3-benzothiazol-6-yl)-N-{4-[(4-isopropylphenyl)amino]-1-phthalazinyl}amine
103	N-(1,3-benzothiazol-6-yl)-N-{4-[(3-methoxyphenyl)amino]-1-phthalazinyl}amine
104	N-(1,3-benzothiazol-6-yl)-N-{4-[(3-fluoro-4-methylphenyl)amino]-1-phthalazinyl}amine
105	N-(1,3-benzothiazol-6-yl)-N-{4-[(4-chlorophenyl)amino]-1-phthalazinyl}amine
106	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 4-methylbenzenesulfonate
107	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 4-chlorobenzenesulfonate
108	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide methanesulfonate
109	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide ethanesulfonatesulfonate
110	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide dihydrochloride
111	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide hydrobromide
112	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide sulfate
113	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide nitrate
114	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 2-hydroxyethanesulfonate
115	4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide benzenesulfonate